Lymphoma, T-Cell Clinical Trial
Official title:
Randomized Phase 3 Study Evaluation the Efficacy and Safety of Oral Azacitidine(CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
This study is a multicentric, open-label, randomized phase 3 trial. The study will be conducted in select countries in Europe and South Korea sponsored by LYSARC and in Japan sponsored by Celgene. There will be a combined enrollment target of 86 randomized patients, with approximately 14 randomized patients from Japan. The enrollment to the randomized study will start at European sites in parallel to a safety run-in part in Japan. A safety run-in will be conducted to confirm the tolerability of oral azacitidine at doses of 100 mg and 200 mg QD in Asian patients. Once oral azacitidine at 200 mg QD is confirmed as tolerable, Asian patients from Japan and South Korea will start to be randomized into the main study. Additional patients (non-randomized) are anticipated to enroll to the safety run-in.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
| Completed |
NCT02158975 -
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
|
Phase 2 | |
| Completed |
NCT00043368 -
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
|
Phase 2 | |
| Completed |
NCT00069238 -
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas
|
Phase 2 | |
| Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05476770 -
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT00038376 -
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
|
Phase 2 | |
| Recruiting |
NCT03161223 -
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03902184 -
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05398614 -
SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT03910283 -
Leveraging Mindsets to Improve Health & Wellbeing in Patients With Cancer
|
N/A | |
| Completed |
NCT04121507 -
ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy
|
Phase 2 | |
| Completed |
NCT04136275 -
CAR-37 T Cells In Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT03921879 -
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma
|
Phase 1 | |
| Terminated |
NCT03154710 -
Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response
|
N/A | |
| Recruiting |
NCT05466318 -
ChiCGB vs BEAM in High-risk or R/R Lymphomas
|
Phase 3 | |
| Recruiting |
NCT04928105 -
Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma
|
N/A | |
| Withdrawn |
NCT04233697 -
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
|
Phase 1 | |
| Completed |
NCT01309789 -
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
|
Phase 1 | |
| Recruiting |
NCT05557903 -
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
|
Phase 1 |